---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-105351"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2023-09-29T23:59:59+00:00"
generated_at: "2026-06-10T06:57:01.346333+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Entrada Therapeutics enters into $150M at-the-market offering agreement with Cowen

## Summary
- Entered into sales agreement with Cowen and Company for at-the-market offering of up to $150M in common stock.
- Cowen will receive a commission of up to 3.0% of gross sales proceeds; Company not obligated to sell any shares.
- Offering made under existing effective shelf registration statement (S-3) filed November 2022.
- Shares will be sold on Nasdaq or other trading markets, subject to instructions and conditions.

## SEC filing metadata
- accession: 0001104659-23-105351
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2023-09-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000110465923105351/0001104659-23-105351-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000110465923105351/tm2327232d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-105351
- JSON: https://secwatch.observer/filing/0001104659-23-105351.json
- Plain text: https://secwatch.observer/filing/0001104659-23-105351.txt

## Key facts
- Material Agreements
  Entrada Therapeutics, Inc. entered into Sales Agreement with Cowen and Company, LLC valued at up to $150.0 million (effective 2023-09-29).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Cowen and Company, LLC
  - Value: up to $150.0 million
  - Effective: 2023-09-29
  source text: On September 29, 2023, Entrada Therapeutics, Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC, acting as the Company’s agent and/or principal (the “Sales Agent”), with respect to an “at the market offering” program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $150.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1689375/000110465923105351/0001104659-23-105351-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.